1. ALLA AKTIER
  2. NYHETER
  3. NEODYNAMICS

NeoDynamics

Nyheter NeoDynamics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

NeoDynamics publishes Annual Report 2023

MARKN.

NeoDynamics AB hereby publishes the annual report for the financial year 2023.

The annual report is attached to this press release and is available on the company's website: https://www.neodynamics.com/sv-se/rapporter

The Annual report is published in Swedish and English. For the purposes of statutory reporting, the Swedish version is the official report and the English version is an unofficial translation of the report.

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2024. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

For further information, please contact:
Matilda Salén, CEO NeoDynamics AB, phone +46 76-843 65 74 or e-mail matilda.salen@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail aaron.wong@neodynamics.com

About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

Attachments
Årsrapport NeoDynamics 2023 SVE
Annual Report NeoDynamics 2023 ENG

Datum 2024-05-01, kl 08:00
Källa MFN
Bifogade filer
Årsrapport NeoDynamics 2023 SVE
Annual Report NeoDynamics 2023 ENG